Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the...
Brain
bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types
Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up...
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn"...
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"...
Wesana Health Announces Change to The Board of Directors
Chicago, Illinois and Toronto, Ontario--(Newsfile Corp. - January 24, 2025) - Wesana Health Holdings Inc. (CSE: WESA.X) (OTC Pink: WSNAF)...
Positron Corporation Secures Agreement to Sell and Rent Eight NeuSight PET-CT Scanners
Niagara Falls, NY, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular...
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care
Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and...
BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals
News Release January 23, 2025 BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals...
Cancer Research UK, Cytovation and the Norwegian Cancer Society collaborate to advance treatment for rare cancer
Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s Centre...
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Nalu Expands MRI-Conditional Labeling for Peripheral Nerve Stimulation with FDA Clearance for Whole-Body MRI
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical announces the FDA clearance for expanded labeling of its Peripheral Nerve Stimulation (PNS) System, now approved...
Nalu Expands MRI-Conditional Labeling for Peripheral Nerve Stimulation with FDA Clearance for Whole-Body MRI
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical announces the FDA clearance for expanded labeling of its Peripheral Nerve Stimulation (PNS) System, now approved...
Biodexa Strengthens Management Team – Appointment of Dr Gary A. Shangold as Chief Medical Officer
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC...
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing...
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population...
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people...
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
New Year – New Goal! Talk it Out NC Advises Parents How to Start The Conversation in 2025
State Initiative to Prevent Underage Drinking Gives Parents and Teens Tools to Make Smart, Safe Decisions RALEIGH, N.C., Jan. 21,...
Percipio Health raises $20M and unveils AI-powered Population Health Monitoring platform
The platform collects and analyzes multiple health signals via smartphone, without medical monitoring devices, to reach broader populations at lower...